3 news items
Where Immunocore Hldgs Stands With Analysts
IMCR
29 Apr 24
their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Immunocore Hldgs
Key Takeaways From Immunocore Hldgs Analyst Ratings
IMCR
29 Feb 24
$72.00
Key Insights:
Action Taken: In response to dynamic market conditions
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
BMY
IMCR
28 Feb 24
monotherapy clinical activity including partial responses (PR), durable tumor reduction, disease control (PR and SD), PFS and circulating tumor DNA
- Prev
- 1
- Next